Clinical trials: Probable Alzheimer Disease
Alzheimer Disease
A Study of Seltorexant in Participants With Probable Alzheimer's Disease
The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with…
- Trial name
- NCT05307692
- Testing
- Seltorexant
- Where
- 25 sites in United States
- Volunteers
- 88 people
- Sponsor
- Janssen Research & Development, LLC
Probable Alzheimer's Disease
Exploratory Open Label Study for Development of a Method To Detect Dendritic Cells
This is a proof-of-concept study designed to confirm that human phagocytic cells can be labeled with the near-infrared dye indocyanine green (ICG) and the presence of the labeled cells 48 hours later in cerebral cortex can be…
- Trial name
- NCT05482867
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- MindImmune Therapeutics, Inc.
Alzheimer's Disease
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
This study will evaluate compliance, tolerability, safety, efficacy and caregiver burden of rivastigmine patch 10 cm² treatment in people with Alzheimer's disease (MMSE 10-26) initiating therapy for the first time with a…
- Trial name
- CARE (NCT00731224)
- Testing
- Rivastigmine transdermal patch
- Where
- 40 sites in Australia, Malaysia and 3 more
- Volunteers
- 380 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
The purpose of this study is to assess the efficacy, safety, and tolerability of Exelon® patch in patients with probable AD (MMSE 10-20), in order to support a planned regulatory submission and registration of Exelon transdermal…
- Trial name
- NCT01399125
- Testing
- Rivastigmine Patch, Rivastigmine Capsules
- Where
- 16 sites in China
- Volunteers
- 501 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study was to investigate the 5cm^2 and 10cm^2 doses of rivastigmine transdermal patch in terms of efficacy and safety in patients with probable Alzheimer's Disease (MMSE [Mini Mental State Examination] 10-20).
- Trial name
- NCT00423085
- Testing
- Rivastigmine transdermal patch
- Where
- Japan
- Volunteers
- 859 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Type Dementia
An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
The purpose of this study is to evaluate the efficacy and safety of two fixed dose (1200mg/day, 1600mg/day) of INM-176 (a drug of treating dementia) comparing with donepezil for treatment for patients with Alzheimer type dementia.
- Trial name
- NCT01245530
- Testing
- Aricept, INM-176
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Whanin Pharmaceutical Company
Agitation,Psychomotor, Disruptive Behavior
A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
This double-blind, placebo-controlled study is designed to assess the effectiveness of, MediCane's medical cannabis oil extracted from MediCane's proprietary strain into GMP-grade olive oil, as an add-on therapy to standard of…
- Conditions
- Agitation,Psychomotor, Disruptive Behavior, Dementia, Alzheimer Disease
- Trial name
- NCT06217146
- Testing
- Medical Cannabis
- Where
- 3 sites in Israel
- Volunteers
- 24 people
- Sponsor
- M. H MediCane Ltd.
Diagnostic Imaging
Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers
PET (positron emission tomography) imaging with BAY85-8102 F-18, DPA-714 for investigation of neuroinflammation pattern in probable Alzheimers patients versus healthy volunteers and radiation dosimetry in healthy volunteer.
- Trial name
- NCT01009359
- Testing
- F-18 DPA-714 (BAY85-8102)
- Where
- 2 sites in Finland, Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bayer
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
The purpose of the study is to evaluate the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate probable Alzheimer's Disease.
- Trial name
- NCT03008161
- Testing
- NPT088
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- Proclara Biosciences, Inc.
Alzheimer's Disease
Safety and Efficacy of MT-4666
The objective of this study is to evaluate the safety and efficacy as assessed by the Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of MT-4666 or placebo administered daily for 24 weeks…
- Trial name
- NCT01764243
- Testing
- MT-4666
- Where
- Japan
- Volunteers
- 450 people
- Sponsor
- Tanabe Pharma Corporation
Alzheimer Disease
ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease
The primary efficacy objective of this study is to test the hypothesis that DBS-f stimulation (ON) will slow cognitive and functional progression of AD, as compared to no stimulation (OFF), by measuring baseline…
- Trial name
- NCT03622905
- Testing
- DBS-f On, DBS Off
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 74 people
- Sponsor
- Functional Neuromodulation Ltd
Alzheimer's Disease, Central Nervous System Diseases
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
This study is being conducted to determine the safety and effect on cognitive function of the investigational medication, EVP-6124, in individuals with mild to moderate probable Alzheimer's disease.
- Conditions
- Alzheimer's Disease, Central Nervous System Diseases, Cognition
- Trial name
- NCT01073228
- Testing
- EVP-6124
- Where
- 54 sites in United States, Romania and 3 more
- Volunteers
- 409 people
- Sponsor
- FORUM Pharmaceuticals Inc
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236431
- Testing
- Galantamine hydrobromide
- Volunteers
- 1,063 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease
The study was performed to compare the safety and efficacy of Cerebrolysin (10 mililiters [ml]), Aricept (10 miligrams [mg]), and a combination of both treatments on cognitive performance and global function in patients with…
- Trial name
- Combi (NCT00911807)
- Testing
- Cerebrolysin + donepezil
- Where
- 3 sites in Spain
- Volunteers
- 217 people
- Sponsor
- Ever Neuro Pharma GmbH
Alzheimer's Disease, Dementia
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
The objective of the study is to define the performance of blood-based signatures for Alzheimer's Disease (AD) in different patients populations including AD, non-AD dementia, and non-demented controls.
- Trial name
- NCT00880347
- Testing
- Blood sampling
- Where
- 21 sites in France
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Exonhit
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Alzheimer's Disease
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderate Alzheimer's Disease.
- Trial name
- NCT04187547
- Testing
- Tricaprilin
- Sponsor
- Cerecin
Diagnostic Imaging
Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers
PET (positron emission tomography) imaging with BAY1006578 for investigation of diagnostic potential in probable Alzheimer Disease patients versus healthy volunteers and radiation dosimetry in healthy volunteers.
- Trial name
- NCT01153607
- Testing
- BAY1006578
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Mild Cognitive Impairment, Alzheimer's Disease
Comparison of PET Amyloid Imaging in Japanese and Western Subjects
This was a Phase 2, multicenter study to assess the extent and patterns of [18F] flutemetamol uptake in the brains of 3 groups of Japanese subjects: healthy volunteers (HV), amnestic mild cognitive impairment (aMCI), and probable…
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Healthy
- Trial name
- NCT02813070
- Testing
- [18F] Flutemetamol
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GE Healthcare